2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-P2612
    WP9QY 199999-60-5 99.78%
    WP9QY is an inhibitor targeting TNFα and RANKL, which blocks the TNFα-TNFR1 interaction and inhibits TNFα-mediated apoptosis, cytotoxicity and bone destruction. WP9QY inhibits osteoclastogenesis and promotes osteoblast differentiation, induces chondrocyte proliferation and glycosaminoglycan production, and synergizes with TGF-β3 to promote chondrogenesis. WP9QY effectively repairs full-thickness articular cartilage defects in rabbits via intra-articular injection, and inhibits methylmercury-induced reduction of NeuN-positive cells in mouse brain slices. WP9QY can be applied to the research of diseases related to methylmercury-induced neuronal death, cartilage injury, osteoarthritis and bone loss.
    WP9QY
  • HY-P3377
    Rimtoregtide 2251722-35-5 98.05%
    Rimtoregtide is a polypeptide compound which significantly reduces the increase in the levels of amylase and lipase in the blood caused by acute pancreatitis. Rimtoregtide has the potential for the research of pancreatitis and acute pancreatitis (extracted from patent WO2018205233A1).
    Rimtoregtide
  • HY-P3485
    GAGGVGKSAL 199477-18-4 99.64%
    GAGGVGKSAL is the wild-type 10-mer KRAS peptide. GAGGVGKSAL serves as a control.
    GAGGVGKSAL
  • HY-P3585
    Epobis 915091-83-7 99.38%
    Epobis, a dendrimeric peptide, is a recombinant form of erythropoietin. Epobis is a potent erythropoietin receptor agonist. Epobis promotes neuritogenesis in primary motoneurons. Epobis decrease TNF release and crosses the blood-brain barrier. Epobis has anti-inflammatory and memory enhancing properties.
    Epobis
  • HY-P3982
    CKLF1-C19 960358-79-6 99.11%
    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4.
    CKLF1-C19
  • HY-P5285
    Lunasin 496823-34-8 98.22%
    Lunasin is a bioactive peptide with antioxidant, anti-inflammatory, anticancer and anti-aging properties. Lunasin can be isolated from soybean. Lunasin also has an epigenetic mechanism of action associated with histone acetylation. Lunasin can be internalized into cells and inhibit Oncosphere formation in cancer cells.
    Lunasin
  • HY-P6312
    ESAT6 Epitope 183273-40-7
    ESAT6 Epitope is a ESAT6 CD4+ T cell epitope. ESAT6 Epitope binds to MHC class I molecules with an IC50 value of approximately 180 nM. ESAT6 Epitope has weak immunogenicity. ESAT6 Epitope can be used in studies related to pulmonary tuberculosis.
    ESAT6 Epitope
  • HY-Y0641
    3-Phenoxybenzaldehyde 39515-51-0 99.74%
    3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity.
    3-Phenoxybenzaldehyde
  • HY-Y1809
    1-Hydroxyoctadecane 112-92-5 99.65%
    1-Hydroxyoctadecane (Stearyl alcohol) is a long-chain fatty alcohol and excipient. 1-Hydroxyoctadecane forms a closed oil film, thereby reducing transepidermal water loss (TEWL) and promoting skin moisturization. 1-Hydroxyoctadecane improves Imiquimod (HY-B0180)-induced psoriatic skin inflammation in mice.
    1-Hydroxyoctadecane
  • HY-100085
    21-Desacetyldeflazacort

    21-Desacetyldeflazacort

    		13649-57-5 98.41%
    21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration.
    21-Desacetyldeflazacort
  • HY-100580
    Asaraldehyde 4460-86-0
    Asarylaldehyde (Asaronaldehyde), a COX-2 inhibitor, significantly inhibits cyclooxygenase II (COX-2) activity with an IC50 value of 100 μg/mL.
    Asaraldehyde
  • HY-101195
    DL-erythro-Dihydrosphingosine 3102-56-5 ≥98.0%
    DL-erythro-Dihydrosphingosine is a sphingosine-based PKC inhibitor. DL-erythro-Dihydrosphingosine directly inhibits the enzymatic activity of PLA2. DL-erythro-Dihydrosphingosine inhibits the activity of Bcl-2 protein involved in apoptosis. DL-erythro-Dihydrosphingosine inhibits the activity of matrix metalloproteinases (MMP). DL-erythro-Dihydrosphingosine is applicable for research on cancer and inflammatory diseases.
    DL-erythro-Dihydrosphingosine
  • HY-101420
    VUF10460 1028327-66-3 99.35%
    VUF10460 is a non-imidazole histamine H4 receptor agonist; binds to rat H4 receptor with a pKi of 7.46.
    VUF10460
  • HY-101762
    TyK2-IN-2 2098466-94-3 ≥98.0%
    TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC50s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC50 of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases.
    TyK2-IN-2
  • HY-103050
    ML-030 1013750-77-0 99.28%
    ML-030 is a potent PDE4 inhibitor, with IC50 of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM for PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2, respectively.
    ML-030
  • HY-103183
    CV1808 53296-10-9 ≥98.0%
    CV1808 (2-Phenylaminoadenosine) is a non-selective A2 adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively.
    CV1808
  • HY-103186
    MRS-1706

    MRS-1706

    		264622-53-9 98.07%
    MRS-1706 is a potent and selective adenosine A2B receptor inverse agonist. MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1 and A3 receptors respectively. MRS-1706 blocks adenosine-mediated cAMP induction.
    MRS-1706
  • HY-103317
    NAADP

    NAADP

    		5502-96-5
    NAADP, a nucleotide, is a Ca2+-mobilizing second messenger. NAADP is essential for initiation of Ca2+ signaling.
    NAADP
  • HY-103347
    M50054 54135-60-3 98.44%
    M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC50 of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia.
    M50054
  • HY-105005
    Crisdesalazine 927685-43-6 98.92%
    Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury.
    Crisdesalazine
製品番号 製品名 / Synonyms Application Reactivity